Yahoo Finance

Ensoma Presents Preclinical Data Demonstrating Potential of In Vivo, HSC-derived CAR-M, NK, and T Platform for Solid Tumors at SITC 2025

Company’s in vivo HSC engineering platform drives durable multi-lineage CAR immune cell generation in mice, addressing key limitations of CAR therapies for solid tumors ...
Business Wire

Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...
Yahoo Finance

Ensoma to Present Clinical Safety Data from First Participant Dosed with In Vivo HSC Engineering Therapy at ASGCT Annual Meeting

Initial Phase 1/2 safety data for EN-374 in X-linked chronic granulomatous disease (X-CGD) demonstrate tolerability in first trial participant Updated preclinical data with Ensoma’s virus-like ...